Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of Niraparib in Chinese Patients with Ovarian Cancer
NCT03551171Phase 1Completed
- Sponsor
- Zai Lab
- Start
- Dec 2017
- Primary completion
- May 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of niraparib in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC) (3 cohorts), sponsored by Zai Lab. Primary endpoints: Maximum plasma drug concentration, Time to reach Cmax and 4 more. Started Dec 2017; status: completed.
02
Drugs
niraparib
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT03551171.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03551171.